Inify Laboratories EGM approves share issuances to bolster financial structure

Inify Laboratories AB held an extraordinary general meeting (EGM) on December 4, 2025, where 66,655,976 shares, representing 84.5 percent of total shares and votes, were represented. The EGM approved the board's proposal for two directed share issuances. The first, a private placement, involves issuing shares to SB1 Markets AS for onward transfer to major shareholders, while the second, a repair issue, is for transfer to other shareholders, also via SB1 Markets AS. Further details and timelines were previously released on November 12, 2025, and December 3, 2025.

Inify Laboratories, headquartered in Stockholm, Sweden, with local labs in Sweden and the UK, specializes in histopathology diagnostics. The company focuses on optimizing patient care pathways, offering integrated services from tissue handling to diagnosis for prostate cancer and gastroenterology. Their scalable operations utilize a fully digital, standardized, and AI-assisted workflow, ensuring high-quality diagnostics with rapid turnaround times.

The company's proprietary AI technology supports pathologists in diagnostics. This tailored system allows for future expansion into additional diagnostic areas. Inify Laboratories' shares are listed on Euronext Growth Oslo.